

# Marat V Ezhov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3122478/publications.pdf>

Version: 2024-02-01

68  
papers

7,630  
citations

361413

20  
h-index

128289

60  
g-index

75  
all docs

75  
docs citations

75  
times ranked

8716  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.   | 2.2  | 4,871     |
| 2  | Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492.  | 1.6  | 533       |
| 3  | Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.   | 5.8  | 238       |
| 4  | Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.   | 1.6  | 232       |
| 5  | The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.   | 2.8  | 216       |
| 6  | Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.   | 0.9  | 206       |
| 7  | Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.   | 0.8  | 163       |
| 8  | Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.   | 13.7 | 142       |
| 9  | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.  | 6.8  | 104       |
| 10 | Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. <i>Atherosclerosis Supplements</i> , 2013, 14, 93-99.  | 1.2  | 102       |
| 11 | Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32. | 1.2  | 90        |
| 12 | The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021, 40, 255-276.   | 5.0  | 75        |
| 13 | Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.  | 13.7 | 69        |
| 14 | Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 613.  | 6.1  | 66        |
| 15 | An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020, 5, 709.   | 6.1  | 63        |
| 16 | Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.  | 3.1  | 39        |
| 17 | Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. <i>Atherosclerosis</i> , 2014, 235, 477-482.  | 0.8  | 38        |
| 18 | Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels. <i>Biomolecules</i> , 2019, 9, 129.  | 4.0  | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.  | 1.2 | 31        |
| 20 | EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) Tj ETQq0 0 0 rgBT /Overlo<br>TREATMENT OF ATHEROSCLEROSIS (2020). <i>Eurasian Heart Journal</i> , 2020, , 6-29.                                | 0.8 | 28        |
| 21 | Lipoprotein(a) Loweringâ€”From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 2103.  | 2.4 | 21        |
| 22 | Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). <i>Russian Journal of Cardiology</i> , 2019, , 7-13.                      | 1.4 | 21        |
| 23 | Lipoprotein(a) apheresis. <i>Current Opinion in Lipidology</i> , 2016, 27, 351-358.   | 2.7 | 17        |
| 24 | Statin therapy in athletes and patients performing regular intense exercise â€” Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.                                     | 7.1 | 17        |
| 25 | Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. <i>Atherosclerosis</i> , 2018, 277, 477-482. | 0.8 | 15        |
| 26 | Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. <i>Atherosclerosis Supplements</i> , 2017, 30, 187-192.   | 1.2 | 14        |
| 27 | Verification of Underlying Genetic Cause in a Cohort of Russian Patients with Familial Hypercholesterolemia Using Targeted Next Generation Sequencing. <i>Journal of Cardiovascular Development and Disease</i> , 2020, 7, 16.            | 1.6 | 14        |
| 28 | The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. <i>Current Atherosclerosis Reports</i> , 2019, 21, 36.                                       | 4.8 | 13        |
| 29 | Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 269.  | 2.5 | 13        |
| 30 | Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 11.   | 1.6 | 12        |
| 31 | Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 68.  | 4.8 | 11        |
| 32 | The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 63.  | 1.6 | 11        |
| 33 | Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion. <i>Russian Journal of Cardiology</i> , 2019, , 44-51.  | 1.4 | 10        |
| 34 | EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.                           | 0.8 | 9         |
| 35 | ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS. <i>Russian Journal of Cardiology</i> , 2018, , 99-109.   | 1.4 | 9         |
| 36 | Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology. <i>Russian Journal of Cardiology</i> , 2021, 26, 4694.                     | 1.4 | 9         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level. <i>Journal of Cardiovascular Development and Disease</i> , 2020, 7, 45.                                     | 1.6 | 7         |
| 38 | Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. <i>Biomolecules</i> , 2021, 11, 257.  | 4.0 | 6         |
| 39 | Organization of lipid centers operation in the Russian Federation – new opportunities. <i>Russian Journal of Cardiology</i> , 2021, 26, 4489.   | 1.4 | 6         |
| 40 | Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2723-2725.  | 3.6 | 4         |
| 41 | The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.   | 2.8 | 4         |
| 42 | Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases. <i>Archives of Medical Science</i> , 2021, , .                                | 0.9 | 4         |
| 43 | Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis. <i>Diseases (Basel)</i> , 2021, 11, 1074.<br>Tj ETQq1 1 0.784314 rgBT <sub>4</sub> /Overlook  | 2.5 | 4         |
| 44 | Features of using of a fixed combination of rosuvastatin and ezetimibe for effective hypolipidemic therapy. <i>Meditinskiy Sovet</i> , 2020, , 26-32.   | 0.5 | 3         |
| 45 | A Clinical Case of a Homozygous Deletion in the APOA5 Gene with Severe Hypertriglyceridemia. <i>Genes</i> , 2022, 13, 1062.   | 2.4 | 3         |
| 46 | Association of various lipid parameters with premature coronary artery disease in men. <i>Russian Journal of Cardiology</i> , 2022, 27, 5058.   | 1.4 | 3         |
| 47 | Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 169-172.                | 0.8 | 2         |
| 48 | Role of inflammation, autotaxin and lipoprotein (a) in degenerative aortic valve stenosis in patients with coronary artery disease. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2598. | 1.4 | 2         |
| 49 | Familial hypercholesterolemia: current status of the problem, treatment, and prevention. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2532.  | 1.4 | 2         |
| 50 | RAISED IgM AUTOANTIBODY TITER TO LIPOPROTEIDE(A) AS ANTIATHEROGENIC FACTOR IN SEVERE HYPERCHOLESTEROLEMIA PATIENTS. <i>Russian Journal of Cardiology</i> , 2018, , 13-20.   | 1.4 | 2         |
| 51 | Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy. <i>Meditinskiy Sovet</i> , 2019, , 21-26.  | 0.5 | 2         |
| 52 | Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome. <i>Russian Journal of Cardiology</i> , 2022, 27, 5041.                                      | 1.4 | 2         |
| 53 | Frequency of familial hypercholesterolemia in patients with premature acute coronary syndrome. <i>Atherosclerosis</i> , 2017, 263, e230-e231.   | 0.8 | 1         |
| 54 | Inflammation markers in coronary heart disease patients with aortic valve stenosis. <i>Russian Journal of Cardiology</i> , 2018, , 17-22.   | 1.4 | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | «Связь между уровнем ЛП(а) и распространенностью атеросклероза у молодых пациентов. Терапевтический Архив, 2022, 94, 479-484.   | 0.8 | 1         |
| 56 | The relationship between the level of Lp(a) and the prevalence of atherosclerosis among young patients. Terapevticheskii Arkhiv, 2022, 94, 479-484.   | 0.8 | 1         |
| 57 | The presence of pathogenic mutations in patients with definite or probable diagnosis of familial hypercholesterolemia defined by targeted next generation sequencing. Atherosclerosis, 2017, 263, e231.   | 0.8 | 0         |
| 58 | High Lipoprotein(a) Level is a Predictor of Peripheral Artery Disease Regardless of the Presence of Type 2 Diabetes. Atherosclerosis Supplements, 2018, 32, 42.   | 1.2 | 0         |
| 59 | RAISED LEVEL OF LIPOPROTEIN(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER EXTREMITIES ARTERIES. Russian Journal of Cardiology, 2018, , 7-12.                       | 1.4 | 0         |
| 60 | Severe hyperlipoproteinemia(a) as a factor of rapidly progressive coronary artery disease in a young woman with heterozygous familial hypercholesterolemia. Russian Journal of Cardiology, 2019, , 72-73. | 1.4 | 0         |
| 61 | Abstract 13769: Assessing the Risk for Cardiovascular Diseases According to Lipoprotein(a) Levels. Circulation, 2020, 142, .  | 1.6 | 0         |
| 62 | Unsolved Issues of Atherosclerosis Prevention and of Adequate Lipid-lowering Therapy in Patients with Acute Ischemic Cerebrovascular Accident. Rational Pharmacotherapy in Cardiology, 2022, 17, 927-930. | 0.8 | 0         |
| 63 | Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk. Atherothrombosis, 2022, 11, 56-75.                     | 0.3 | 0         |
| 64 | Atorvastatin: old friend in the light of novel coronavirus infection's pandemic. Meditsinskiy Sovet, 2022, , 82-88.   | 0.5 | 0         |
| 65 | Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review. Kardiologicheskii Vestnik, 2022, 17, 84.  | 0.4 | 0         |
| 66 | Lipoprotein(a) concentration and the blood content of INF $\gamma$ -producing T-helpers 17 (Th17/1) in males with premature coronary artery disease. Russian Journal of Cardiology, 2022, 27, 5046.       | 1.4 | 0         |
| 67 | News of the 90th Congress of the European Society of Atherosclerosis (EAS), Milan May 21-25, 2022. Russian Journal of Cardiology, 2022, 27, 5097.   | 1.4 | 0         |
| 68 | News of the 90th Congress of the European Society of Atherosclerosis (EAS), Milan May 21-25, 2022. Russian Journal of Cardiology, 2022, 27, 5097.   | 1.4 | 0         |